Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 5/20 | 0.40 |
| ▸ | CTSB | P07858 | 5/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829384 | 0.88 | HRH3 (0.51) | HRH3CTSLCTSBCTSSCTSK | |
| SCHEMBL11482610 | 0.88 | PDE4A (0.56) | PDE4ANUDT1HRH4KMT2A | |
| Hydrochloric Acid SCHEMBL28609085 | 0.86 | HRH3 (0.50) | HRH3CTSLCTSBCTSSCTSK | |
| SCHEMBL4837213 | 0.85 | CTSS (0.48) | PDE4AHRH3CTSLCTSBCTSS | |
| SCHEMBL21959070 | 0.82 | CTSL (0.49) | PDE4AHRH3CTSLCTSBCTSS | |
| SCHEMBL27628560 | 0.81 | PDE4A (0.50) | PDE4ANUDT1HRH4KMT2A | |
| SCHEMBL3774476 | 0.81 | PDE4A (0.46) | PDE4ACTSLCTSBCTSSCTSK | |
| Hydrochloric Acid SCHEMBL21876067 | 0.80 | CTSL (0.48) | PDE4AHRH3CTSLCTSBCTSS | |
| SCHEMBL6017006 | 0.79 | HRH4 (0.48) | PDE4ANUDT1HRH4IKBKBIDH2 | |
| SCHEMBL10706738 | 0.78 | NUDT1 (0.43) | PDE4ANUDT1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7163943-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | PDE4A 3011/4885HRH3 1023/4885CTSL 2846/4885 |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | PDE4A 3288/4885HRH3 478/4885CTSL 2784/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | PDE4A 3011/4885HRH3 1023/4885CTSL 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.